The company’s exhibitions will be focused in the areas of its pipeline, proprietary capsid engineering, and manufacturing. Thousand Oaks, Calif.-based Capsida Biotherapeutics (Capsida) has announced ...
Jason F. Cole has been working to make gene therapy a reality for patients since he joined Bluebird about ten years ago. This gave him a front-row seat to the first generation of gene therapies, ...
HANGZHOU, China, May 14, 2025--(BUSINESS WIRE)--Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying multiplexable genome editing technology ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today ...
On Nov. 21, 2016, the American Society of Gene & Cell Therapy (ASGCT) released Therapeutic Gene Editing: an ASGCT White Paper, intended to provide policy-makers, patient advocates, and the interested ...
Title: Autologous human peripheral blood B cells genetically engineered to express human iduronidase: Results from a first-in-human clinical trial in subjects with mucopolysaccharidosis type I (MPS I) ...
- FORCE Delivers to CNS in Non-Human Primates -- FORCE Achieves Robust Reduction of Toxic Nuclear DMPK RNA and Foci in Brain of a DM1 Disease Model - The FORCE platform was designed to overcome the ...
SAN DIEGO--(BUSINESS WIRE)--Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results